The Global Demand for Generic Cancer Medicines and the Top Oncology Medicine Manufacturer
Available at a lower cost, these bridge affordability gaps in cancer treatment.
Generic oncology drugs comprise 80% of the total volume of drug prescriptions.
The oncology injectable forms 5O% of the share.
Hospital pharmacies depend upon 52% of generic oncology drug distribution.
The affordable generics serve as a lifeline for low- and middle-income countries.
- Ensure long –term supplies –
The generic drug manufacturer builds a consistent drug supply, reducing the burden on a single brand.
-
- Cost–saving – They are affordable, ensure and reduce financial burdens on healthcare systems.
- Expand global treatment access-
Generic drugs help expand treatment access beyond borders.
Generic Oncology Medicines: Turning Expensive Care into Essential Care
Expensive treatments have led to failure in access to treatment.
Generic drugs cost up to 80 percent of branded drugs.
The generic options increase market competition, forcing reduced prices.
It reduces the financial constraints on families/ healthcare systems.
The standard first-line generic chemotherapy drugs are listed as essential medicines by the WHO.
Which are the common generic cancer drugs?
- Cisplatin – Cycokast
- Carboplatin – Carbokast
- Paclitaxel – Paclikast
- Docetaxel – Docekast
- Imatinib – Imatikast
- Letrozole – Letrakast
How are generic cancer drugs manufactured?
Generic drugs are the brand-equivalent medicines.
They have the same active ingredient, bioavailability, safety, and efficacy as the branded drugs.
These follow a similar manufacturing process, undergo the same approvals and quality assurance.
The manufacturing of oncology drugs requires dedicated facilities and prevention of cross-contamination.
Isolated facilities: These are separate facilities for manufacturing cytotoxic drugs.
Laminated surfaces – The walls and roof are sealed.
It prevents any particulate contamination.
Air handling systems (HVAC) – These maintain negative air pressure to prevent cross–contamination.
Limited access – The manufacturing area is restricted. Only the working person can enter.
Unidirectional flow processes –Sealed pipelines and closed system transfers to prevent vapor flow in the room.
Validation /decontamination protocols- Equipment validation, surface cleaning, and clean rooms are necessary to prevent contamination.
Sterile operations – These include aseptic processing for injectables.
Personnel safety – Protective gear and clothing are used to prevent working staff from exposure to toxic drugs.
What makes Aprazer Healthcare the largest generic cancer medicine manufacturer?
Aprazer Healthcare leads the way in manufacturing anticancer drugs.
We are the leading cancer medicine exporters from India.
World-class infrastructure:
- Advanced technology
- Modern equipment’s
- In-house testing
- WHO-GMP compliant units
Regulatory adherence/compliance –
We hold licenses and accreditation by global health authorities like WHO-GMP and EU-GMP.
We are a globally accepted oncology medicine manufacturer.
Robust quality control parameters-
We follow a set of SOPs to ensure manufacturing processes and validation.
- In-house quality audits and checks.
- Strong purity control parameters.
- Finished product testing and stability protocols
Supply chain traceability – We ensure quality and authenticity from procuring the raw material to the finished dosage formulation.
Largest product portfolio-
We manufacturer of a wide range of oncology orals and oncology injectables.
Our anticancer product portfolio spans-
- Chemotherapy medicines
- Targeted therapy medicines
- Hormone therapy medicines
Worldwide distribution network –
We are the leading oncology drug exporter from India.
Leveraging advanced logistics technology, we are committed to delivering products on time, preserving integrity.
Aprazer Healthcare aims to make oncology care affordable and universal.
